Evolus Stock (NASDAQ:EOLS)
Previous Close
$16.46
52W Range
$7.44 - $17.59
50D Avg
$13.53
200D Avg
$12.51
Market Cap
$1.10B
Avg Vol (3M)
$524.55K
Beta
1.31
Div Yield
-
EOLS Company Profile
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
EOLS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. |
| ITCI | Intra-Cellular Therapies, Inc. |
| ANIP | ANI Pharmaceuticals, Inc. |
| PAHC | Phibro Animal Health Corporation |
| IXHL | Incannex Healthcare Limited |
| SSIC | Silver Spike Investment Corp. |
| DCPH | Deciphera Pharmaceuticals, Inc. |
| PROC | Procaps Group S.A. |
| PBH | Prestige Consumer Healthcare Inc. |
| ALKS | Alkermes plc |
| PCRX | Pacira BioSciences, Inc. |
| COLL | Collegium Pharmaceutical, Inc. |
| EGRX | Eagle Pharmaceuticals, Inc. |
| AMPH | Amphastar Pharmaceuticals, Inc. |